

Cimetidine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.0	14.04.2025	4242356-00012	Date of first issue: 03.05.2019

Section 1: Identification

Product name : Cimetidine Formulation

Manufacturer or supplier's details

Company : MSD

Address : 33 Whakatiki Street - Private Bag 908
Upper Hutt - New Zealand

Telephone : 0800 800 543

Emergency telephone number : 0800 764 766 (0800 POISON) 0800 243 622 (0800
CHEMCALL)

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

Restrictions on use : Not applicable

Section 2: Hazard identification**GHS Classification**

Reproductive toxicity : Category 1

Specific target organ toxicity - : Category 2 (Liver, Kidney, Testis)
repeated exposure (Oral)

GHS label elements

Hazard pictograms :



Signal word : Danger

Hazard statements : H360D May damage the unborn child.
H373 May cause damage to organs (Liver, Kidney, Testis)
through prolonged or repeated exposure if swallowed.

Precautionary statements : **Prevention:**
P201 Obtain special instructions before use.
P280 Wear protective gloves/ protective clothing/ eye protec-
tion/ face protection.

Cimetidine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.0	14.04.2025	4242356-00012	Date of first issue: 03.05.2019

Response:

P308 + P313 IF exposed or concerned: Get medical advice/attention.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Additional Labelling

The following percentage of the mixture consists of ingredient(s) with unknown hazards to the aquatic environment: 40 %

Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

Section 3: Composition/information on ingredients

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
cimetidine	51481-61-9	>= 30 -< 50
Cellulose	9004-34-6	>= 10 -< 20
Starch	9005-25-8	>= 1 -< 10
Magnesium stearate	557-04-0	>= 1 -< 10

Section 4: First-aid measures

General advice	: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	: If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	: In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	: If in eyes, rinse well with water. Get medical attention if irritation develops and persists.
If swallowed	: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.
Most important symptoms	: Contact with dust can cause mechanical irritation or drying of

Cimetidine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.0	14.04.2025	4242356-00012	Date of first issue: 03.05.2019

and effects, both acute and delayed		the skin. Dust contact with the eyes can lead to mechanical irritation. May damage the unborn child. May cause damage to organs through prolonged or repeated exposure if swallowed.
Protection of first-aiders	:	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	:	Treat symptomatically and supportively.

Section 5: Fire-fighting measures

Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO ₂) Dry chemical
Unsuitable extinguishing media	:	None known.
Specific hazards during fire-fighting	:	Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion products	:	Carbon oxides Nitrogen oxides (NO _x) Sulphur oxides Metal oxides
Specific extinguishing methods	:	Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for firefighters	:	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

Section 6: Accidental release measures

Personal precautions, protective equipment and emergency procedures	:	Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

Cimetidine Formulation

Version	Revision Date:	SDS Number:	Date of last issue:
4.0	14.04.2025	4242356-00012	30.09.2023
			Date of first issue: 03.05.2019

Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

Section 7: Handling and storage

Technical measures	: Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
Local/Total ventilation	: If sufficient ventilation is unavailable, use with local exhaust ventilation.
Advice on safe handling	: Do not get on skin or clothing. Do not breathe dust. Do not swallow. Avoid contact with eyes. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment Keep container tightly closed. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the environment.
Hygiene measures	: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.
Conditions for safe storage	: Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.
Materials to avoid	: Do not store with the following product types:

Cimetidine Formulation

Version 4.0 Revision Date: 14.04.2025 SDS Number: 4242356-00012 Date of last issue: 30.09.2023
 Date of first issue: 03.05.2019

Strong oxidizing agents

Section 8: Exposure controls/personal protection

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
cimetidine	51481-61-9	TWA	1000 µg/m ³ (OEB 1)	
Cellulose	9004-34-6	WES-TWA	10 mg/m ³	NZ OEL
		TWA	10 mg/m ³	ACGIH
Starch	9005-25-8	WES-TWA	10 mg/m ³	NZ OEL
		TWA	10 mg/m ³	ACGIH
Magnesium stearate	557-04-0	WES-TWA	10 mg/m ³	NZ OEL
		TWA (Inhalable particulate matter)	10 mg/m ³	ACGIH
		TWA (Respirable particulate matter)	3 mg/m ³	ACGIH

Engineering measures : Use feasible engineering controls to minimize exposure to compound.
 All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection : Chemical-resistant gloves

Material

Eye protection : Wear safety glasses with side shields or goggles.
 If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
 Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat.

Section 9: Physical and chemical properties

Appearance : powder

Colour : No data available

Cimetidine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.0	14.04.2025	4242356-00012	Date of first issue: 03.05.2019

Odour	:	No data available
Odour Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	Not applicable
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	Not applicable
Relative vapour density	:	Not applicable
Relative density	:	No data available
Density	:	No data available
Solubility(ies)		
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	Not applicable
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.

Cimetidine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.0	14.04.2025	4242356-00012	Date of first issue: 03.05.2019

Molecular weight : No data available

Particle characteristics
Particle size : No data available

Section 10: Stability and reactivity

Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.
Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.
Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.
Avoid dust formation.

Incompatible materials : Oxidizing agents
Hazardous decomposition products : No hazardous decomposition products are known.

Section 11: Toxicological information

Exposure routes : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Components:**cimetidine:**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg
LD50 (Mouse): 2,550 mg/kg
LD50 (Hamster): > 4,000 mg/kg

Acute toxicity (other routes of administration) : LD50 (Rat): 106 mg/kg
Application Route: Intravenous
LD50 (Rabbit): 164 mg/kg
Application Route: Intravenous
LD50 (Rat): 860 mg/kg
Application Route: Subcutaneous
LD50 (Mouse): 437 mg/kg
Application Route: Subcutaneous
Symptoms: Convulsions

Cimetidine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.0	14.04.2025	4242356-00012	Date of first issue: 03.05.2019

Cellulose:

Acute oral toxicity	: LD50 (Rat): > 5,000 mg/kg
Acute inhalation toxicity	: LC50 (Rat): > 5.8 mg/l Exposure time: 4 h Test atmosphere: dust/mist
Acute dermal toxicity	: LD50 (Rabbit): > 2,000 mg/kg

Starch:

Acute oral toxicity	: LD50 (Rat): > 5,000 mg/kg
Acute dermal toxicity	: LD50 (Rabbit): > 2,000 mg/kg

Magnesium stearate:

Acute oral toxicity	: LD50 (Rat): > 2,000 mg/kg Method: OECD Test Guideline 423 Assessment: The substance or mixture has no acute oral toxicity Remarks: Based on data from similar materials
Acute dermal toxicity	: LD50 (Rabbit): > 2,000 mg/kg Remarks: Based on data from similar materials

Skin corrosion/irritation

Not classified based on available information.

Components:**Magnesium stearate:**

Species	: Rabbit
Result	: No skin irritation
Remarks	: Based on data from similar materials

Serious eye damage/eye irritation

Not classified based on available information.

Components:**Starch:**

Species	: Rabbit
Result	: No eye irritation

Magnesium stearate:

Species	: Rabbit
Result	: No eye irritation
Remarks	: Based on data from similar materials

Cimetidine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.0	14.04.2025	4242356-00012	Date of first issue: 03.05.2019

Respiratory or skin sensitisation**Skin sensitisation**

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:**Starch:**

Test Type	: Maximisation Test
Exposure routes	: Skin contact
Species	: Guinea pig
Result	: negative

Magnesium stearate:

Test Type	: Maximisation Test
Exposure routes	: Skin contact
Species	: Guinea pig
Method	: OECD Test Guideline 406
Result	: negative
Remarks	: Based on data from similar materials

Chronic toxicity**Germ cell mutagenicity**

Not classified based on available information.

Components:**cimetidine:**

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative
	Test Type: Chromosomal aberration Result: negative
	Test Type: unscheduled DNA synthesis assay Test system: rat hepatocytes Result: negative
	Test Type: unscheduled DNA synthesis assay Result: negative

Cellulose:

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative
	Test Type: In vitro mammalian cell gene mutation test Result: negative

Cimetidine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.0	14.04.2025	4242356-00012	Date of first issue: 03.05.2019

Genotoxicity in vivo	: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Ingestion Result: negative
----------------------	--

Starch:

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative
-----------------------	--

Magnesium stearate:

Genotoxicity in vitro	: Test Type: In vitro mammalian cell gene mutation test Result: negative Remarks: Based on data from similar materials Test Type: Chromosome aberration test in vitro Method: OECD Test Guideline 473 Result: negative Remarks: Based on data from similar materials Test Type: Bacterial reverse mutation assay (AMES) Result: negative Remarks: Based on data from similar materials
-----------------------	---

Carcinogenicity

Not classified based on available information.

Components:**cimetidine:**

Species	: Rat
Application Route	: Oral
Exposure time	: 2 Years
Target Organs	: Testis
Remarks	: Benign tumor(s)

Carcinogenicity - Assessment	: No evidence of carcinogenicity in animal studies.
------------------------------	---

Cellulose:

Species	: Rat
Application Route	: Ingestion
Exposure time	: 72 weeks
Result	: negative

Reproductive toxicity

May damage the unborn child.

Cimetidine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.0	14.04.2025	4242356-00012	Date of first issue: 03.05.2019

Components:**cimetidine:**

- | | | |
|------------------------------------|---|--|
| Effects on fertility | : | Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Oral
Fertility: NOAEL: 950 mg/kg body weight
Result: No effect on reproduction capacity |
| Effects on foetal development | : | Test Type: Development
Species: Rat
Application Route: Oral
Developmental Toxicity: LOAEL: 17 mg/kg body weight
Symptoms: male reproductive effects
Remarks: Adverse effects were observed in males only. |
| Reproductive toxicity - Assessment | : | May damage the unborn child. |

Cellulose:

- | | | |
|-------------------------------|---|---|
| Effects on fertility | : | Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative |
| Effects on foetal development | : | Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Ingestion
Result: negative |

Magnesium stearate:

- | | | |
|-------------------------------|---|--|
| Effects on fertility | : | Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 422
Result: negative
Remarks: Based on data from similar materials |
| Effects on foetal development | : | Test Type: Embryo-foetal development
Species: Rat
Application Route: Ingestion
Result: negative
Remarks: Based on data from similar materials |

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

May cause damage to organs (Liver, Kidney, Testis) through prolonged or repeated exposure if swallowed.

Cimetidine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.0	14.04.2025	4242356-00012	Date of first issue: 03.05.2019

Components:**cimetidine:**

Exposure routes	: Oral
Target Organs	: Liver, Kidney, Testis
Assessment	: May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Components:****cimetidine:**

Species	: Rat
LOAEL	: 160 mg/kg
Application Route	: Oral
Exposure time	: 2 Months
Target Organs	: Gastrointestinal tract
Remarks	: May cause damage to organs.

Species	: Rat
NOAEL	: 200 mg/kg
Application Route	: Oral
Exposure time	: 12 Months
Symptoms	: No adverse effects

Species	: Rat
LOAEL	: 950 mg/kg
Application Route	: Oral
Exposure time	: 2 yr
Target Organs	: Liver, Testis, Prostate
Remarks	: May cause damage to organs.

Species	: Dog
NOAEL	: 366 mg/kg
Application Route	: Oral
Exposure time	: 12 Months
Target Organs	: Liver, Kidney, Prostate
Remarks	: May cause damage to organs.

Species	: Dog
NOAEL	: 144 mg/kg
Application Route	: Oral
Exposure time	: 4 yr
Symptoms	: No adverse effects

Cellulose:

Species	: Rat
NOAEL	: >= 9,000 mg/kg
Application Route	: Ingestion
Exposure time	: 90 Days

Cimetidine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.0	14.04.2025	4242356-00012	Date of first issue: 03.05.2019

Starch:

Species	: Rat
NOAEL	: $\geq 2,000$ mg/kg
Application Route	: Skin contact
Exposure time	: 28 Days
Method	: OECD Test Guideline 410

Magnesium stearate:

Species	: Rat
NOAEL	: > 100 mg/kg
Application Route	: Ingestion
Exposure time	: 90 Days
Remarks	: Based on data from similar materials

Aspiration toxicity

Not classified based on available information.

Experience with human exposure**Components:****cimetidine:**

Ingestion	: Symptoms: The most common side effects are:, Headache, Dizziness, Nausea, skin rash, Itching, May cause, central nervous system effects, gynecomastia, impotence, kidney effects Remarks: May cause harm to breast-fed children.
-----------	---

Section 12: Ecological information**Ecotoxicity****Components:****cimetidine:****Ecotoxicology Assessment**

Acute aquatic toxicity	: Toxic effects cannot be excluded
Chronic aquatic toxicity	: Toxic effects cannot be excluded

Cellulose:

Toxicity to fish	: LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l Exposure time: 48 h Remarks: Based on data from similar materials
------------------	--

Magnesium stearate:

Toxicity to fish	: LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l
------------------	---

Cimetidine Formulation

Version	Revision Date:	SDS Number:	Date of last issue:
4.0	14.04.2025	4242356-00012	30.09.2023
			Date of first issue: 03.05.2019

	Exposure time: 48 h Method: DIN 38412 Remarks: Based on data from similar materials
Toxicity to daphnia and other aquatic invertebrates	: EL50 (Daphnia magna (Water flea)): > 1 mg/l Exposure time: 47 h Test substance: Water Accommodated Fraction Method: Directive 67/548/EEC, Annex V, C.2. Remarks: Based on data from similar materials No toxicity at the limit of solubility
Toxicity to algae/aquatic plants	: EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l Exposure time: 72 h Test substance: Water Accommodated Fraction Method: OECD Test Guideline 201 Remarks: Based on data from similar materials No toxicity at the limit of solubility
	NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l Exposure time: 72 h Test substance: Water Accommodated Fraction Method: OECD Test Guideline 201 Remarks: Based on data from similar materials
Toxicity to microorganisms	: EC10 (Pseudomonas putida): > 100 mg/l Exposure time: 16 h Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials

Persistence and degradability**Components:****Cellulose:**

Biodegradability	: Result: Readily biodegradable.
------------------	----------------------------------

Magnesium stearate:

Biodegradability	: Result: Not biodegradable Remarks: Based on data from similar materials
------------------	--

Bioaccumulative potential**Components:****cimetidine:**

Partition coefficient: n-octanol/water	: log Pow: 0.40
--	-----------------

Magnesium stearate:

Cimetidine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.0	14.04.2025	4242356-00012	Date of first issue: 03.05.2019

Partition coefficient: n-octanol/water : log Pow: > 4

Mobility in soil

No data available

Other adverse effects

No data available

Section 13: Disposal considerations**Disposal methods**

Waste from residues	: Do not dispose of waste into sewer. Dispose of in accordance with local regulations.
Contaminated packaging	: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

Section 14: Transport information**International Regulations****UNRTDG**

UN number	: Not applicable
Proper shipping name	: Not applicable
Class	: Not applicable
Subsidiary risk	: Not applicable
Packing group	: Not applicable
Labels	: Not applicable
Environmentally hazardous	: no

IATA-DGR

UN/ID No.	: Not applicable
Proper shipping name	: Not applicable
Class	: Not applicable
Subsidiary risk	: Not applicable
Packing group	: Not applicable
Labels	: Not applicable
Packing instruction (cargo aircraft)	: Not applicable
Packing instruction (passenger aircraft)	: Not applicable

IMDG-Code

UN number	: Not applicable
Proper shipping name	: Not applicable
Class	: Not applicable
Subsidiary risk	: Not applicable
Packing group	: Not applicable
Labels	: Not applicable
EmS Code	: Not applicable
Marine pollutant	: Not applicable

Cimetidine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.0	14.04.2025	4242356-00012	Date of first issue: 03.05.2019

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

National Regulations**NZS 5433**

UN number	:	Not applicable
Proper shipping name	:	Not applicable
Class	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable
Hazchem Code	:	Not applicable

Special precautions for user

Not applicable

Section 15: Regulatory information**Safety, health and environmental regulations/legislation specific for the substance or mixture****HSNO Approval Number**

HSR100425 Pharmaceutical Active Ingredients Group Standard

Tolerable Exposure Limits (TEL)

Not applicable

Environmental Exposure Limits (EEL)

Not applicable

HSW Controls

Certified handler certificate not required.

Tracking hazardous substance not required.

Refer to the Health and Safety at Work (Hazardous Substances) Regulations 2017, for further information.

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

Section 16: Other information

Revision Date : 14.04.2025

Further information

Sources of key data used to compile the Safety Data Sheet	:	Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, http://echa.europa.eu/
---	---	---

Cimetidine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.0	14.04.2025	4242356-00012	Date of first issue: 03.05.2019

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : dd.mm.yyyy

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)
NZ OEL : New Zealand. Workplace Exposure Standards for Atmospheric Contaminants

ACGIH / TWA : 8-hour, time-weighted average
NZ OEL / WES-TWA : Workplace Exposure Standard - Time Weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

SAFETY DATA SHEET



Cimetidine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.0	14.04.2025	4242356-00012	Date of first issue: 03.05.2019

NZ / EN